The Food and Drug Administration’s accelerated approval program aims to speed “approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint” of overall survival (progression-free survival). Overall survival is usually considered the gold standard in oncology because people with cancer generally want to take medications that can help them live longer. So judging the FDA’s accelerated approval program without assessing its full impact on overall survival presents a very slanted story.
Case in point: Under the seemingly benign title, “Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval,” an article published recently in the Journal of the American Medical Association claims that among “cancer drugs granted accelerated approval from 2013 to 2017, 41% (19/46) did not improve overall survival or quality of life in confirmatory trials after more than 5 years of follow-up, with results not yet available for another 15%.”
Click this link for the original source of this article.
Author: Peter J. Pitts and Timothy R. Franson
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.